PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2025-03-21			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 11.1M 9.57M 8.8M 8.28M 15.57M 1.05B 15.7M 104M 40.61M 514M 41.65M 40.76M 1.78B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 15.74M 13.58M 12.48M 11.75M 22.08M 1.49B 22.26M 148M 57.59M 729M 59.07M 57.81M 2.52B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
24-08-21	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
24-06-24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
24-06-20	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
24-01-15	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
23-12-20	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
23-12-14	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
23-05-31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
23-05-31	PCL to Raise 36 Billion Won via Share Issuance	MT
23-03-22	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
22-12-28	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	430,000
10 years	5,900	523,333.33

PCL, Inc. Stock

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	2024-03-27
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	2024-03-27

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	73	-
Mu-Yong So BRD	Director/Board Member	53	2024-03-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-88.17%	11.14M
VERACYTE, INC.	+0.73%	+6.48%	+91.67%	+96.59%	4.06B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-2.56%	-1.70%	+65.48%	+100.00%	2.76B
BGI GENOMICS CO., LTD.	+0.56%	+1.30%	-31.97%	-41.39%	1.93B
IOVANCE BIOTHERAPEUTICS, INC.	+2.88%	+3.97%	+94.55%	-51.60%	1.71B
CAREDX, INC.	+0.99%	+0.09%	+20.29%	+194.97%	1.2B
SEEGENE, INC.	+3.51%	+6.31%	-11.81%	+23.69%	871M
MARAVAI LIFESCIENCES HOLDINGS, INC.	+4.19%	+2.76%	+149.76%	-62.12%	739M
CURIOX BIOSYSTEMS CO., LTD	+5.97%	-5.06%	+68.25%	-	707M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-2.50%	-6.67%	-30.65%	-17.20%	531M
Average	+1.21%	+0.34%	+41.56%	+17.20%	1.45B
Weighted average by Cap.	+0.84%	+2.30%	+55.75%	+50.62%

	2023	2024
Net sales	8.43B 5.57M 4.8M 4.41M 4.16M 7.81M 525M 7.87M 52.32M 20.37M 258M 20.89M 20.45M 892M	1.25B 823K 710K 653K 614K 1.15M 77.66M 1.16M 7.73M 3.01M 38.11M 3.09M 3.02M 132M
Net income	-20.32B -13.42M -11.57M -10.64M -10.02M -18.82M -1.27B -18.98M -126M -49.1M -621M -50.36M -49.28M -2.15B	-52.34B -34.56M -29.82M -27.41M -25.8M -48.48M -3.26B -48.89M -325M -126M -1.6B -130M -127M -5.54B
Net Debt	7.2B 4.76M 4.1M 3.77M 3.55M 6.67M 449M 6.73M 44.71M 17.41M 220M 17.85M 17.47M 762M	7.03B 4.64M 4M 3.68M 3.47M 6.51M 438M 6.57M 43.64M 16.99M 215M 17.42M 17.05M 744M